Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors

Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces the appointment of Mohammad Sharifi to the Wellbeing Board of Directors ("the Board"), effective November 22, 2022. Mr. Mohammad Sharifi will serve as a member of the Audit Committee and Governance Committee of the Board.

"We are pleased to welcome Mohammad to the Board," said Najla Guthrie, CEO of Wellbeing. "Mohammad's leadership experience will be invaluable to the Company as we grow our business and pursue our mission to enrich lives through enhanced mental health services."

Mr. Sharifi has extensive experience in marketing and digital communications which has spanned across the consumer products industry. Mr. Sharifi has also held various senior marketing roles at several companies, including Telus Telecommunication where he was responsible for the growth and marketing of their business. Mohammad joins at a key point in the Company's growth and his knowledge and experience will be vital as we continue our plans to fundamentally change the mental health industry by providing the research, education, and distribution needed to make innovative treatments accessible.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:
Najla Guthrie
Chief Executive Officer
WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company's business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.